GLP-1 Drugs Are the Breakthrough for Weight Loss in Heart Failure — But Caution Is Needed in Advanced HFrEF | Research

The takeaway

GLP-1 agonists have proven safe and effective for weight loss in obesity-related HFpEF (STEP-HFpEF), but safety concerns persist for advanced heart failure with reduced ejection fraction (HFrEF).

STEP-HFpEF: safe and effective
Semaglutide 2.4 mg confirmed for weight loss in obesity-related HFpEF, but caution advised in HFrEF

What the researchers found

GLP-1 agonists (semaglutide) are confirmed safe and effective for weight loss in obesity-related HFpEF, but evidence for safety in advanced HFrEF is limited and warrants caution.

Why it matters

Obesity worsens heart failure prognosis, but weight loss options for HF patients have been limited and risky. The STEP-HFpEF results open a new treatment avenue for HFpEF, but clinicians need clear guidance on which HF patients are appropriate candidates.

The numbers in context

Review covers HFrEF and HFpEF; highlights STEP-HFpEF program results with semaglutide; discusses bariatric surgery and lifestyle data.

How the study worked

Clinical review covering obesity management in heart failure, including lifestyle, bariatric surgery, and pharmacotherapy with focus on GLP-1 and GIP/GLP-1 agonists.

Who was studied

Heart failure patients with obesity (HFrEF and HFpEF)

What this study cannot tell us

Review article — no new data. STEP-HFpEF data applies to HFpEF, not HFrEF. Safety concerns in HFrEF are based on smaller, earlier studies. Tirzepatide data in HF is emerging. Long-term weight maintenance after GLP-1 discontinuation in HF patients is unknown.

How to read the evidence

Moderate evidence — review incorporating strong RCT data (STEP-HFpEF) for HFpEF and limited/concerning data for HFrEF.

When this study was published

Published in 2024. Reflects the post-STEP-HFpEF evidence landscape for weight management in heart failure.

The bigger picture

The obesity-heart failure relationship is bidirectional, and effective weight management could break this cycle. GLP-1 drugs represent the most significant pharmacological advance in this space, but the HFrEF safety question needs to be resolved before they can be broadly recommended across all heart failure phenotypes.

Questions still open

Will dedicated trials clarify GLP-1 agonist safety in HFrEF?
Can tirzepatide offer even greater benefits than semaglutide for obesity-related HFpEF?
What is the optimal weight loss target for HF patients — and does it differ by HF type?

Common questions

Can heart failure patients safely take weight loss drugs?

It depends on the type of heart failure. For obesity-related HFpEF (where the heart pumps normally but is stiff), semaglutide has been proven safe and effective in large clinical trials. But for HFrEF (where the heart pumps weakly), there are safety concerns, and more research is needed before GLP-1 drugs can be recommended.

Why is weight loss important for heart failure patients?

Obesity makes heart failure worse — extra weight puts more strain on the heart, increases inflammation, and worsens symptoms. Effective weight loss can improve heart failure symptoms, exercise capacity, and quality of life. The challenge has been finding weight loss methods that are safe for people with heart problems.

Read the original research

Obesity and Weight Loss Strategies for Patients With Heart Failure.

JACC. Heart failure, 12(9), 1509-1527

View on PubMed ↗Publisher’s paper ↗

Citation

Vest, Amanda R; Schauer, Philip R; Rodgers, Jo E; Sanderson, Emily; LaChute, Courtney L; Seltz, Jessica; Lavie, Carl J; Mandras, Stacy A; Tang, W H Wilson; daSilva-deAbreu, Adrian. (2024). Obesity and Weight Loss Strategies for Patients With Heart Failure.. JACC. Heart failure, 12(9), 1509-1527. https://doi.org/10.1016/j.jchf.2024.06.006